MENS PE Ratio & Valuation,Is MENS Overvalued — Intellectia
MENS Relative Valuation
MENS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MENS is overvalued; if below, it's undervalued.
Historical Valuation
Jyong Biotech Ltd(MENS) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of0.00.The fair price ofJyong Biotech Ltd(MENS)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：15.40
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Jyong Biotech Ltd. (MENS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Jyong Biotech Ltd. (MENS) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Jyong Biotech Ltd. (MENS) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Jyong Biotech Ltd. (MENS) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Jyong Biotech Ltd. (MENS) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Jyong Biotech Ltd (MENS) has a current Price-to-Book (P/B) ratio of -30.18. Compared to its 3-year average P/B ratio of -71.06 , the current P/B ratio is approximately -57.53% higher. Relative to its 5-year average P/B ratio of -71.06, the current P/B ratio is about -57.53% higher. Jyong Biotech Ltd (MENS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.21%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.21% , the current FCF yield is about -100.00% lower.
-30.18
P/B
Median3y
-71.06
Median5y
-71.06
-0.21
FCF Yield
Median3y
-0.21
Median5y
-0.21
Competitors Valuation Multiple
The average P/S ratio for MENS's competitors is 0.00, providing a benchmark for relative valuation. Jyong Biotech Ltd Corp (MENS) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MENS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MENS in the past 1 year is driven by Unknown.
Is Jyong Biotech Ltd (MENS) currently overvalued or undervalued?
Jyong Biotech Ltd(MENS)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of0.00.The fair price of Jyong Biotech Ltd(MENS)is betweentoaccording to relative valuation methord.
What is Jyong Biotech Ltd (MENS) fair value?
MENS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Jyong Biotech Ltd (MENS) is between to according to relative valuation methord.
How does MENS's valuation metrics compare to the industry average?
The average P/S ratio for MENS's competitors is 0.00, providing a benchmark for relative valuation. Jyong Biotech Ltd Corp (MENS) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Jyong Biotech Ltd (MENS) as of Dec 17 2025?
As of Dec 17 2025, Jyong Biotech Ltd (MENS) has a P/B ratio of -30.18. This indicates that the market values MENS at -30.18 times its book value.
What is the current FCF Yield for Jyong Biotech Ltd (MENS) as of Dec 17 2025?
As of Dec 17 2025, Jyong Biotech Ltd (MENS) has a FCF Yield of 0.00%. This means that for every dollar of Jyong Biotech Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Jyong Biotech Ltd (MENS) as of Dec 17 2025?
As of Dec 17 2025, Jyong Biotech Ltd (MENS) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Jyong Biotech Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Jyong Biotech Ltd (MENS) as of Dec 17 2025?
As of Dec 17 2025, Jyong Biotech Ltd (MENS) has a Forward P/S ratio of 0.00. This means the market is valuing MENS at $0.00 for every dollar of expected revenue over the next 12 months.
